When I was doing Diabetes CME for clinicians and pharmacists I had a couple of slides that showed a patient hooked up to a machine as big as a small car. This device was able to control glucose levels way back in the 70’s. The question we used to ask …

Man, 52 years of age, with obesity and type 2 diabetes, was switched from daily liraglutide (Victoza) 1.8mg to weekly semaglutide (Ozempic) 0.25mg. I was very clear with patient about the switch being from a daily injection to a weekly and that we would be increasing the semaglutide weekly.

In this week's Homerun Slides, a closer look at the Systolic Blood Pressure Intervention Trial (SPRINT).

The foregoing observations have detailed the best established risk factors associated with insulin resistance as well some novel emerging risk factors as additionally detailed in Table 23.2, including nutritional measures such as Vitamin D. These are not comprehensive but rather a selection of emerging pathways of interest. Clearly, future research should increasingly harness genetics as well as observational data to better determine causal risk pathways. Similarly, further data are needed to better determine the extent to which insulin resistance is, or is not, linked to cardiovascular risk.

Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.Review: Need …

Major adverse CV and cerebrovascular events with noncardiac sx have also increased in DM patients

Findings show MHO is transient, so not a reliable predictor of lower cardiovascular risk in the future

Frequency of primary outcome was 27.6 and 23.4 percent in glyburide and insulin groups, respectively